The AST/ALT (De Ritis) ratio as a significant prognostic factor in myelodysplastic syndrome
Background: The aspartate transaminase (AST)/alanine transaminase (ALT) ratio, also termed the De Ritis ratio, has been demonstrated to have an association with poor prognosis in several cancer types. However, its prognostic value in patients with myelodysplastic syndrome (MDS) remains unclear. Meth...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | All Life |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/26895293.2024.2343710 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593465723060224 |
|---|---|
| author | Ying Chen Yue Wu Ting Chen Duobing Zou Cong Shi Ningning Wu Lixia Sheng Guifang Ouyang Qitian Mu |
| author_facet | Ying Chen Yue Wu Ting Chen Duobing Zou Cong Shi Ningning Wu Lixia Sheng Guifang Ouyang Qitian Mu |
| author_sort | Ying Chen |
| collection | DOAJ |
| description | Background: The aspartate transaminase (AST)/alanine transaminase (ALT) ratio, also termed the De Ritis ratio, has been demonstrated to have an association with poor prognosis in several cancer types. However, its prognostic value in patients with myelodysplastic syndrome (MDS) remains unclear. Methods: A total of 265 MDS patients were divided into two groups by R. The clinical, laboratory, and follow-up data of patients with MDS were collected, while the relationship between AST/ALT ratio and overall survival (OS) and leukemia-free survival (LFS) were also analyzed. Results: The results showed that higher AST/ALT ratio was associated with higher age, β2-microglobulin level, and number of co-mutations (>4). Moreover, the high AST/ALT group had a significantly shorter OS and LFS than the low AST/ALT group. Multivariate analysis involving the Revised International Prognostic Scoring System (IPSS-R) showed that a higher AST/ALT ratio was an independent adverse factor for OS or LFS; however, the same was not noted in the multivariate analysis involving the new Molecular International Prognostic Scoring System (IPSS-M). Conclusions: Our study suggests that the AST/ALT ratio could be a simple and economic prognostic indicator for MDS and be used as a supplement to IPSS-R, especially when lacking of karyotype or mutation data. |
| format | Article |
| id | doaj-art-4ac908e5bf3c469581385471a2db0dcc |
| institution | Kabale University |
| issn | 2689-5307 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | All Life |
| spelling | doaj-art-4ac908e5bf3c469581385471a2db0dcc2025-01-20T14:38:00ZengTaylor & Francis GroupAll Life2689-53072024-12-01170110.1080/26895293.2024.23437102343710The AST/ALT (De Ritis) ratio as a significant prognostic factor in myelodysplastic syndromeYing Chen0Yue Wu1Ting Chen2Duobing Zou3Cong Shi4Ningning Wu5Lixia Sheng6Guifang Ouyang7Qitian Mu8The First Affiliated Hospital of Ningbo UniversityThe First Affiliated Hospital of Ningbo UniversityNingbo UniversityThe First Affiliated Hospital of Ningbo UniversityThe First Affiliated Hospital of Ningbo UniversityThe First Affiliated Hospital of Ningbo UniversityNingbo Clinical Research Center For Hematologic MalignanciesNingbo Clinical Research Center For Hematologic MalignanciesThe First Affiliated Hospital of Ningbo UniversityBackground: The aspartate transaminase (AST)/alanine transaminase (ALT) ratio, also termed the De Ritis ratio, has been demonstrated to have an association with poor prognosis in several cancer types. However, its prognostic value in patients with myelodysplastic syndrome (MDS) remains unclear. Methods: A total of 265 MDS patients were divided into two groups by R. The clinical, laboratory, and follow-up data of patients with MDS were collected, while the relationship between AST/ALT ratio and overall survival (OS) and leukemia-free survival (LFS) were also analyzed. Results: The results showed that higher AST/ALT ratio was associated with higher age, β2-microglobulin level, and number of co-mutations (>4). Moreover, the high AST/ALT group had a significantly shorter OS and LFS than the low AST/ALT group. Multivariate analysis involving the Revised International Prognostic Scoring System (IPSS-R) showed that a higher AST/ALT ratio was an independent adverse factor for OS or LFS; however, the same was not noted in the multivariate analysis involving the new Molecular International Prognostic Scoring System (IPSS-M). Conclusions: Our study suggests that the AST/ALT ratio could be a simple and economic prognostic indicator for MDS and be used as a supplement to IPSS-R, especially when lacking of karyotype or mutation data.http://dx.doi.org/10.1080/26895293.2024.2343710myelodysplastic syndromesast/alt ratioprognosisipss-ripss-m |
| spellingShingle | Ying Chen Yue Wu Ting Chen Duobing Zou Cong Shi Ningning Wu Lixia Sheng Guifang Ouyang Qitian Mu The AST/ALT (De Ritis) ratio as a significant prognostic factor in myelodysplastic syndrome All Life myelodysplastic syndromes ast/alt ratio prognosis ipss-r ipss-m |
| title | The AST/ALT (De Ritis) ratio as a significant prognostic factor in myelodysplastic syndrome |
| title_full | The AST/ALT (De Ritis) ratio as a significant prognostic factor in myelodysplastic syndrome |
| title_fullStr | The AST/ALT (De Ritis) ratio as a significant prognostic factor in myelodysplastic syndrome |
| title_full_unstemmed | The AST/ALT (De Ritis) ratio as a significant prognostic factor in myelodysplastic syndrome |
| title_short | The AST/ALT (De Ritis) ratio as a significant prognostic factor in myelodysplastic syndrome |
| title_sort | ast alt de ritis ratio as a significant prognostic factor in myelodysplastic syndrome |
| topic | myelodysplastic syndromes ast/alt ratio prognosis ipss-r ipss-m |
| url | http://dx.doi.org/10.1080/26895293.2024.2343710 |
| work_keys_str_mv | AT yingchen theastaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT yuewu theastaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT tingchen theastaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT duobingzou theastaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT congshi theastaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT ningningwu theastaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT lixiasheng theastaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT guifangouyang theastaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT qitianmu theastaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT yingchen astaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT yuewu astaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT tingchen astaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT duobingzou astaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT congshi astaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT ningningwu astaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT lixiasheng astaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT guifangouyang astaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome AT qitianmu astaltderitisratioasasignificantprognosticfactorinmyelodysplasticsyndrome |